Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
08 February 2019 | Story Thabo Kessah | Photo Thabo Kessah
Gateway 2019
From the left: Mookgo Mofokeng, Lethukuthula Nsibande, Siyalungelwa Ntombela, and Chulumanco Mazwi.

The two-week Gateway Orientation programme to introduce first-year students to campus and faculty life on the Qwaqwa Campus,  has been a resounding success – if the first-years’ comments are anything to go by.

“Amazing Race was for me the pinnacle of this programme, as it enabled me to get to know the campus much better. It was such a refreshing experience, despite my sore thighs that are still hurting. I also loved the Step Up for success initiative,” said Chulumanco Mazwi from Mthatha in the Eastern Cape. Chulumanco has enrolled for a BAdmin degree, which will “enable me to interact with people, particularly in the corporate world”.

From Paballong Village in Qwaqwa came a budding scientist, Mookgo Mofokeng. “The programme has afforded me the opportunity to interact with a number of students from different places such as KwaZulu-Natal, Eastern Cape, and Gauteng,” she said. “I have also learnt about the history of the campus that is very close to my heart,” said Mookgo. “This is the campus where I won the prize for my Eskom Expo for Young Scientists project, with my partner and I displaying our water-extracting project as learners from the Beacon Secondary School here in Qwaqwa. For more on this, please watch the environmental television programme 50/50 on SABC 2 on 17 February 2019.”

Coming from Newcastle in KwaZulu-Natal is ‘the future businessman in the computing sector’, Lethukuthula Nsibande. “The Gateway orientation programme was so much fun, as it enabled me to see teamwork as an integral part of our development as first-years. Considering that I want to pursue business in the interesting world of computers, I have seen that interacting with others is crucial,” said Lethukuthula, a BSc IT (Computer Science and Management) student.

From Johannesburg, Gauteng, comes Siyalungelwa Ntombela, a BEd (Intermediate Phase – Life Sills and Social Sciences) student who believes her studies will enable her to give back to her community. “I want to educate our future generations and make a difference. I found Gateway to be educational and entertaining. We have learnt a lot about university life and the campus in general. I now know about the services offered by the clinic, where the Mandela Hall is, and so on. Interacting and learning from our mentors was also one of the highlights,” she added.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept